Organization
Schön Klinik Hamburg Eilbek, Hamburg, Germany
3 abstracts
Abstract
ASSESSMENT OF DISABILITY LEVELS IN A COHORT OF 1,489 PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS, AND THE EFFECT OF APREMILAST TREATMENT: POOLED DATA FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS Org: Swedish Medical Center and University of Washington School of Medicine, Seattle, United States, Schön Klinik Hamburg Eilbek, Hamburg, Germany, Monash University, CabriniHealth, Melbourne, Australia, UZ Gent, Gent, Belgium, University of Orléans, Orléans, France,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENT IN MEASURES OF DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM 3 PHASE 3, RANDOMIZED, CONTROLLED TRIALS Org: University of California San Diego, San Diego, United States, University of Genova, Genova, Italy, Swedish Medical Center and University of Washington School of Medicine, Seattle, United States, Toronto Western Hospital, Toronto, Canada, University of Sheffield, Sheffield, United Kingdom,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN BASDAI IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS Org: Swedish Medical Center and University of Washington School of Medicine, Seattle, United States, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, Clinical Research Centre Ltd, Tartu, Estonia, UZ Gent, Gent, Belgium, Schön Klinik Hamburg Eilbek, Hamburg, Germany,